微信公众号

官网二维码
中国癌症防治杂志

中国癌症防治杂志 ›› 2025, Vol. 17 ›› Issue (2): 145-149.doi: 10.3969/j.issn.1674-5671.2025.02.03

• 癌情监测 • 上一篇    下一篇

肝癌住院患者生存特征分析：基于广西某肿瘤医院的十年队列随访（2010—2020年）

  

  1. 广西医科大学附属肿瘤医院疾病流程管理办公室；广西医科大学附属肿瘤医院科研科；广西医科大学附属肿瘤医院肿瘤防控办公室；广西医科大学附属肿瘤医院肝胆胰脾外科；广西医科大学附属肿瘤医院实验研究部；广西壮族自治区卫生健康委员会肿瘤分子医学重点(培育)实验室；广西壮族自治区肿瘤分子医学工程研究中心；广西医科大学附属肿瘤医院信息中心
  • 出版日期:2025-04-25 发布日期:2025-05-15
  • 通讯作者: 吕汉斌 E-mail：85793513@qq.com
  • 基金资助:
    广西自然科学基金重点项目区域高发疾病研究联合专项资助(2024GXNSFDA010040）；广西医疗卫生适宜技术开发与推广应用项目（S2022112）；广西壮族自治区卫生健康委员会自筹经费科研课题（Z?A20240717）

Analysis of survival characteristics in liver cancer inpatients: a 10-year follow-up cohort from a cancer hospital in Guangxi (2010—2020)

  • Online:2025-04-25 Published:2025-05-15

PDF (PC)

16

赞

摘要： 目的 分析2010—2020年广西某肿瘤医院肝癌住院患者的生存状况。方法 基于医院登记系统，采用被动与主动随访相结合，对2010年1月至2020年12月于广西某肿瘤医院住院的肝癌患者进行随访，随访截止时间为2024年8月6日。采用Kaplan⁃Meier法计算生存率，Wilcoxon秩和检验分析年龄别、性别、巴塞罗那肝癌临床（Barcelona clinic liver cancer,BCLC）分期及不同时期患者的生存差异。结果 共纳入12 177例肝癌患者，平均年龄（60.03±11.79）岁，男性占比高于女性（86.19% vs 13.81%）。总体中位生存时间为14.53个月，1、3、5及10年生存率分别为52.25%、34.20%、28.11%和19.89%，男性患者各时期生存率均低于女性（P<0.001）。不同年龄组患者生存曲线差异有统计学意义（P=0.002），其中<40岁组（26.73%）和≥80岁组（19.06%）患者的5年生存率均低于40~79岁组（27.97%~29.76%）。BCLC A期、B期、C期及D期患者的5年生存率分别为69.56%、42.95%、15.72%、6.20%（P<0.001）。2010—2015年患者的1、3、5年生存率分别为50.49%、32.49%、26.41%，2016—2020年提升至53.72%、35.60%、29.45%，差异有统计学意义（P<0.001）。结论 2016—2020年广西肝癌住院患者远期生存率呈显著升高趋势，但仍处于较低水平，青年/老年、男性、BCLC 高分期患者生存率仍面临挑战，应作为临床重点关注人群，并继续加强肝癌的综合防控措施。

关键词: 肝癌, 肿瘤登记, 医院登记, 随访, 生存率

Abstract: Objective To analyze survival status of liver cancer inpatients in a cancer hospital in Guangxi from 2010 to 2020. Methods Based on the hospital registration system, an active⁃passive follow⁃up was performed for liver cancer inpatients in a cancer hospital in Guangxi from January 2010 to December 2020, with follow⁃up ending on August 6, 2024. Kaplan⁃Meier survival analysis was used to calculate survival rates. Wilcoxon rank⁃sum was used to analyze survival differences by age, sex, Barcelona Clinical Liver Cancer (BCLC), and treatment periods. Results A total of 12, 177 liver cancer patients were included, with an average age of （60.03±11.79） years, and a higher proportion of males than females (86.19% vs 13.81%). The median overall survival was 14.53 months, with 1⁃, 3⁃, 5⁃, and 10⁃year survival rates of 52.25%, 34.20%, 28.11%, and 19.89%, respectively, the survival rate of male patients was lower than that of female patients at all timepoints (P<0.001). The survival curves differed statistically significant among age groups, with lower 5⁃year survival rates in the <40 (26.55%) and ≥80 (19.21%) age groups compared with the 40-79 age group (27.97%-28.48%). The 5⁃year survival rates of patients in BCLC stages A, B, C, and D were 69.56%, 42.95%, 15.72%, and 6.20%, respectively (P<0.001). The 1⁃, 3⁃, and 5⁃year survival rates for patients from 2010 to 2015 were 50.49%, 32.49%, and 26.41%, respectively, which improved to 53.72%, 35.60%, and 29.45% during 2016—2020, with statistically significant differences (P<0.001). Conclusions The long⁃term survival rates of liver cancer inpatients in Guangxi from 2016 to 2020 showed a significant upward trend, but remained at a relatively low level. Patients with young/old age, male, and advanced BCLC stages still face challenges in survival rates, and should be prioritized  focus. Comprehensive prevention and control measures for liver cancer should be further strengthened.

Key words: Liver Cancer, Cancer registry, Hospital registry, Follow?up, Survival rate

中图分类号: 

  •